These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2491941)

  • 21. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
    Golbe LI; Lieberman AN; Muenter MD; Ahlskog JE; Gopinathan G; Neophytides AN; Foo SH; Duvoisin RC
    Clin Neuropharmacol; 1988 Feb; 11(1):45-55. PubMed ID: 3127050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions.
    Contreras-Mora H; Rowland MA; Yohn SE; Correa M; Salamone JD
    Pharmacol Biochem Behav; 2018 Mar; 166():13-20. PubMed ID: 29309800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Peselow ED; Gershon S
    Psychopharmacol Bull; 1982 Oct; 18(4):182-4. PubMed ID: 6818606
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of L-Deprenyl on on-off phenomena in Parkinson's disease.
    Brodersen P; Philbert A; Gulliksen G; Stigård A
    Acta Neurol Scand; 1985 Jun; 71(6):494-7. PubMed ID: 3927650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
    Rascol O; Montastruc JL; Senard JM; Demonet JF; Simonetta M; Rascol A
    Neurology; 1988 Sep; 38(9):1387-91. PubMed ID: 3137488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.
    Frankel JP; Kempster PA; Stibe CM; Eatough VM; Nathanson M; Lees AJ; Stern GM
    Clin Neuropharmacol; 1989 Oct; 12(5):448-51. PubMed ID: 2514981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness.
    Pare CM; Al Mousawi M; Sandler M; Glover V
    J Affect Disord; 1985 Sep; 9(2):137-41. PubMed ID: 2932486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive effects of L-deprenyl in Alzheimer's disease.
    Tariot PN; Sunderland T; Weingartner H; Murphy DL; Welkowitz JA; Thompson K; Cohen RM
    Psychopharmacology (Berl); 1987; 91(4):489-95. PubMed ID: 3108930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selegiline transdermal system: a novel treatment option for major depressive disorder.
    Nandagopal JJ; DelBello MP
    Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. R-(-)-deprenyl in the treatment of end-of-dose akinesia.
    Ulm G; Fornadi F
    J Neural Transm Suppl; 1987; 25():163-72. PubMed ID: 3123603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose regimen of deprenyl (selegiline) and platelet MAO activities.
    Oreland L; Johansson F; Ekstedt J
    Acta Neurol Scand Suppl; 1983; 95():87-9. PubMed ID: 6428150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyramine-induced noradrenaline release from rat brain slices: prevention by (-)-deprenyl.
    Glover V; Pycock CJ; Sandler M
    Br J Pharmacol; 1983 Sep; 80(1):141-8. PubMed ID: 6418254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW; Hemrick-Luecke SK; Perry KW
    J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use.
    Simpson GM; Frederickson E; Palmer R; Pi E; Sloane RB; White K
    Biol Psychiatry; 1985 Jun; 20(6):684-7. PubMed ID: 3922441
    [No Abstract]   [Full Text] [Related]  

  • 39. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    Bodkin JA; Amsterdam JD
    Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J
    Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.